Anzeige
Meldung des Tages: Antimon vor dem Durchbruch? 50 Mio. Bewertung trifft Milliarden-Fantasie!

Nuvalent Aktie News

Aktie
WKN:  A3CWDU ISIN:  US6707031075 US-Symbol:  NUVL Branche:  Biotechnologie Land:  USA
100,39 $
-3,67 $
-3,53%
84,952 € 20.02.26
Depot/Watchlist
Marktkapitalisierung *
5,06 Mrd. €
Streubesitz
-
KGV
-18,06
Index-Zuordnung
-

Nuvalent News

05.02.26 - PR Newswire
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 PR Newswire
12.01.26 - PR Newswire
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones PR Newswire
22.12.25 - PR Newswire
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
10.12.25 - PR Newswire
Nuvalent Appoints Ron Squarer to Board of Directors
Nuvalent Appoints Ron Squarer to Board of Directors PR Newswire
26.11.25 - PR Newswire
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference PR Newswire
24.11.25 - PR Newswire
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders PR Newswire
19.11.25 - PR Newswire
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-​treated Patients with Advanced ROS1-positive NSCLC PR Newswire
18.11.25 - PR Newswire
Nuvalent Announces Pricing of Public Offering of Common Stock
Nuvalent Announces Pricing of Public Offering of Common Stock PR Newswire
17.11.25 - PR Newswire
Nuvalent Announces Public Offering of Common Stock
Nuvalent Announces Public Offering of Common Stock PR Newswire
17.11.25 - PR Newswire
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-​treated Patients with Advanced ALK-​positive NSCLC PR Newswire
14.11.25 - PR Newswire
Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib
Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-​treated Patients with Advanced ALK-​positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib PR Newswire
04.11.25 - PR Newswire
Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer
Nuvalent to Present Patient-​Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung ...
30.10.25 - PR Newswire
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results PR Newswire
18.10.25 - PR Newswire
Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025
Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-​positive Solid Tumors Beyond NSCLC at ESMO 2025 PR Newswire
13.10.25 - PR Newswire
Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-​NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PR ...
24.09.25 - PR Newswire
Nuvalent to Participate in the UBS 2025 Virtual Oncology Day
Nuvalent to Participate in the UBS 2025 Virtual Oncology Day PR Newswire
07.09.25 - PR Newswire
Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025
Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-​treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 PR Newswire
28.08.25 - PR Newswire
Nuvalent to Participate in the Cantor Global Healthcare Conference 2025
Nuvalent to Participate in the Cantor Global Healthcare Conference 2025 PR Newswire
13.08.25 - PR Newswire
Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium
Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-​treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential ...
07.08.25 - PR Newswire
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results PR Newswire

Newssuche

Videos

newspaper
18.02.26 0,00%
Technical Trading: Chance mit 82 Prozent Treffern
Rohöl Long Typ: Turbo Open End WKN: VH65XQ Hebel:6 Laufzeit: OpenEnd Einstieg: Market ... Mehr »